NDUFA13 (4F12) Monoclonal Antibody

$Lane 1: MCF-7 Cells; Probed with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:1000, overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: MCF-7 Cells; Probed with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:1000, overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with NDUFA13 (4F12) Monoclonal Antibody (bsm-54398R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human

Overview
Catalog #	bsm-54398R
Product Name	NDUFA13 (4F12) Monoclonal Antibody
Applications	WB, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein within human GRIM19 aa 1-150.
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	51079
Swiss Prot	Q9P0J0
Subcellular location	Nucleus, Mitochondrion
Synonyms	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13; Cell death regulatory protein GRIM-19; Complex I-B16.6; Gene associated with retinoic and interferon-induced mortality 19 protein; NADH-ubiquinone oxidoreductase B16.6 subunit; CI-B16.6; GRIM-19; Gene associated with retinoic and IFN-induced mortality 19 protein; NDUFA13; GRIM19
Background	Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death. This apoptotic activity is inhibited by interaction with viral IRF1. Prevents the transactivation of STAT3 target genes. May play a role in CARD15-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200